Two-Drug combo targets Hard-to-Treat melanoma

NCT ID NCT04356729

Ongoing Disease control Sponsor: F. Stephen Hodi, MD Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This trial investigates whether combining atezolizumab (a drug that boosts the immune system) with bevacizumab (a drug that blocks blood vessel growth) can shrink tumors in people with advanced melanoma that cannot be removed by surgery or has spread. The study focuses on patients whose tumors lack a protein called PD-L1, which often makes standard immunotherapy less effective. Participants receive both drugs intravenously every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced melanoma that does not respond to standard immunotherapy.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination may cause side effects like high blood pressure or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 STAGE IV MELANOMA UNRESECTABLE STAGE III CUTANEOUS MELANOMA UNRESECTABLE STAGE IV CUTANEOUS MELANOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital

Boston, Massachusetts, 02214, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.